Spark Therapeutics Enters into Definitive Merger Agreement with Roche
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Mizuho Securities Downgrades Spark Therapeutics (ONCE) to Neutral Following Acquisition
February 25, 2019 8:55 AM ESTMizuho Securities analyst Difei Yang downgraded Spark Therapeutics (NASDAQ: ONCE) from Buy to Neutral with a price target of $114.50.
For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.
Shares of Spark Therapeutics closed at $113.85 yesterday.
... More